Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 3/20 | 0.33 |
| ▸ | HTR1B | P28222 | 3/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404367 | 0.77 | AHR (0.40) | AHRCYP2A6PARP1ATMHTR1D | |
| SCHEMBL19948493 | 0.75 | AHR (0.39) | AHRCYP2A6NR4A2RHEBPRKCI | |
| SCHEMBL13425079 | 0.74 | AHR (0.38) | AHRPARP1ATMGPR84HTR1D | |
| SCHEMBL3248883 | 0.74 | TYR (0.38) | AHRPARP1ATMHTR1DHTR1B | |
| SCHEMBL8529419 | 0.74 | AXL (0.48) | AHRNR4A2PARP1RHEBPRKCI | |
| SCHEMBL8246801 | 0.74 | AHR (0.38) | AHRCYP2A6PARP1ATMHTR1D | |
| SCHEMBL29415607 | 0.74 | TYR (0.38) | AHRPARP1ATMHTR1DHTR1B | |
| SCHEMBL13442150 | 0.74 | AHR (0.42) | AHRPARP1ATMHTR1DHTR1B | |
| SCHEMBL13065414 | 0.74 | AHR (0.47) | AHRCYP2A6NR4A2PARP1GPR84 | |
| SCHEMBL8995172 | 0.74 | AHR (0.52) | AHRCYP2A6NR4A2PARP1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025026955-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| CN-114040914-B | Quinazolinone derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| CN-113912609-B | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | 江苏大学 | 2024-01-05 | — | — | CN | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | AHR 419/4885CYP2A6 1276/4885NR4A2 354/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AHR 2218/4885CYP2A6 3834/4885NR4A2 3870/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | AHR 122/4885CYP2A6 405/4885NR4A2 289/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AHR 2218/4885CYP2A6 3834/4885NR4A2 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.